Cantor Fitzgerald maintains Vertex stock Overweight with $535 target

On Tuesday, Cantor Fitzgerald reiterated its Overweight rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with a price target of $535.00. According to InvestingPro data, this target aligns with the broader analyst consensus, as the stock currently trades near its Fair Value. With a market capitalization of $112.6 billion, Vertex maintains its position as a prominent player in the Biotechnology industry. The reiteration follows Vertex’s first-quarter earnings report, which showed results slightly below consensus expectations, particularly for its drug Alyftrek. Despite this, the company’s management countered concerns regarding slowing growth and confirmed the accuracy of third-party reported retail channel volumes. InvestingPro analysis reveals that Vertex maintains strong financial health with a current ratio of 2.69 and operates with a moderate level of debt, suggesting robust operational stability. Get access to 12 more exclusive ProTips and comprehensive analysis with an InvestingPro subscription.

Vertex’s earnings were marked by sales of Alyftrek that did not meet the expectations set by Visible Alpha, a provider of investment research technology. Additionally, the reported sales of Journavx, another drug by Vertex, were negligible. However, the company’s management responded to these figures by raising the lower end of their financial guidance for the year by $100 million.

The financial analyst from Cantor Fitzgerald, Carter Gould, noted that the results for Alyftrek and Journavx were largely anticipated by their estimates. Gould also highlighted that the sales ramp for Journavx is expected to be more significant in the second half of 2025 and into 2026, aligning with previous communications from the company.

Vertex’s stock experienced a slight decline of 3% in after-hours trading following the earnings release. Nevertheless, Gould expressed the belief that any negative impact on the stock would be transient. This aligns with the stock’s historical pattern of low price volatility, as indicated by its beta of 0.51. Year-to-date, VRTX has delivered a strong return of 24.2%, demonstrating resilient performance despite market fluctuations. The raised guidance is seen as a positive sign, indicating the company’s confidence in its growth trajectory despite the quarter’s modest shortfall.

The focus for investors and analysts will likely remain on the long-term performance of Vertex’s portfolio, particularly the anticipated growth in Journavx sales in the coming months. Vertex’s management has maintained a consistent message regarding the expected ramp-up, which could be a critical factor for the company’s performance moving forward. With revenue growth of 11.7% in the last twelve months and analysts expecting continued profitability, the company’s outlook remains promising. For deeper insights into Vertex’s growth potential and comprehensive financial analysis, access the detailed Pro Research Report available exclusively on InvestingPro.

In other recent news, Vertex Pharmaceuticals has reported its first-quarter 2025 earnings, revealing a shortfall in both earnings per share (EPS) and revenue. The company posted an EPS of $4.06, missing the forecast of $4.26, and revenue of $2.77 billion, falling short of the anticipated $2.86 billion. Despite the earnings miss, Vertex raised its 2025 revenue guidance to a range of $11.85 billion to $12 billion. Meanwhile, Bernstein analysts have raised their price target for Vertex to $462, maintaining a Market Perform rating, due to the company’s resilience in the market. Stifel analysts have reiterated a Hold rating with a $194 price target, emphasizing the company’s ongoing efforts to establish a reliable supply chain for its new drug, Journavx. Scotiabank (TSX:BNS), on the other hand, has lowered its price target to $442, citing lower-than-expected revenues and earnings. Additionally, Leerink Partners downgraded Vertex from Outperform to Market Perform and reduced its price target to $503, reflecting tempered expectations for Journavx’s sales and market access.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.